

Application No.: 10/027,218


Case No.: 54913US111

Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (I):



(I)

wherein

R₁ is -C₂₋₄ alkyl-NR₃-CO-R₄ wherein **R₄** is aryl, substituted aryl, heteroaryl, substituted heteroaryl, or alkyl;

R₂ is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- alkyl-O-aryl;
- alkyl -O-alkyl;

Application No.: 10/027,218

Case N .: 54913US111

-alkyl-O-alkenyl; and
 -alkyl or alkenyl substituted by one or more substituents selected from the group
 consisting of:

-OH;
 -halogen;
 -N(R₃)₂;
 -CO-N(R₃)₂;
 -CO-C₁₋₁₀ alkyl;
 -CO-O-C₁₋₁₀ alkyl;
 -N₃;
 -aryl;
 -(substituted aryl);
 -heteroaryl;
 -(substituted heteroaryl);
 -heterocyclyl;
 -(substituted heterocyclyl);
 -CO-aryl; and
 -CO-heteroaryl;

each R₃ is independently selected from the group consisting of hydrogen; C₁₋₁₀ alkyl-heteroaryl; C₁₋₁₀ alkyl-(substituted heteroaryl); C₁₋₁₀ alkyl-aryl; C₁₋₁₀ alkyl-(substituted aryl) and C₁₋₁₀ alkyl;

n is 0 to 4;

and each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl,


wherein the substituent(s) of the substituted aryl are independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy, nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl,

Application No.: 10/027,218

Case No.: 54913US111

alkanoyloxy, and alkanoylthi; or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

2. (original) The composition of claim 1 wherein R_3 is hydrogen.
3. (original) The composition of claim 1 wherein R_2 is selected from the group consisting of hydrogen; C_{1-4} alkyl; and C_{1-4} alkyl-O- C_{1-4} alkyl.
4. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (Ib):



(Ib)

wherein

R_1 is $-C_{2-4}$ alkyl- NR_3 -CO- R_4 wherein R_4 is heterocyclyl or substituted heterocyclyl;

R_2 is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);

Application N .: 10/027,218

Case No.: 54913US111

-heterocyclyl;
-(substituted heterocyclyl);
-alkyl-O-aryl;
-alkyl -O-alkyl;
-alkyl-O-alkenyl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

-OH;
-halogen;
-N(R₃)₂;
-CO-N(R₃)₂;
-CO-C₁₋₁₀ alkyl;
-CO-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-(substituted aryl);
-heteroaryl;
-(substituted heteroaryl);
-heterocyclyl;
-(substituted heterocyclyl);
-CO-aryl; and
-CO-heteroaryl;

each R₃ is independently selected from the group consisting of hydrogen; C₁₋₁₀ alkyl-heteroaryl; C₁₋₁₀ alkyl-(substituted heteroaryl); C₁₋₁₀ alkyl-aryl; C₁₋₁₀ alkyl-(substituted aryl) and C₁₋₁₀ alkyl;


n is 0 to 4;

and each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

Application No.: 10/027,218

Case No.: 54913US111

5. (original) A compound of the formula (Id):



(Id)

wherein

R_1 is $-\text{C}_{2-4}$ alkyl- NR_3 -CO- R_4 wherein R_4 is heteroaryl or substituted heteroaryl;

R_2 is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- alkyl-O-aryl;
- alkyl -O-alkyl;
- alkyl-O-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

Application No.: 10/027,218

Case No.: 54913US111

-OH;
-halogen;
-N(R₃)₂;
-CO-N(R₃)₂;
-CO-C₁₋₁₀ alkyl;
-CO-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-(substituted aryl);
-heteroaryl;
-(substituted heteroaryl);
-heterocyclyl;
-(substituted heterocyclyl);
-CO-aryl; and
-CO-heteroaryl;

each R₃ is independently selected from the group consisting of hydrogen; C₁₋₁₀ alkyl-heteroaryl; C₁₋₁₀ alkyl-(substituted heteroaryl); C₁₋₁₀ alkyl-aryl; C₁₋₁₀ alkyl-(substituted aryl) and C₁₋₁₀ alkyl;

n is 0 to 4;

and each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.

6. (original) A compound of claim 5 wherein n is 0.


7. (original) A compound of claim 5 wherein R₂ is selected from the group consisting of hydrogen, C₁₋₄ alkyl, and C₁₋₄ alkyl-O-C₁₋₄ alkyl.

8. (original) A compound of claim 5 wherein R₃ is hydrogen.

Application N .: 10/027,218

Case N .: 54913US111

9. (original) A compound of the formula (Ie):



(Ie)

whercin

R₁ is -C₂₋₄ alkyl-NR₃-CO-C₁₋₈ alkyl;

R₂ is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- alkyl-O-aryl;
- alkyl -O-alkyl;
- alkyl-O-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

- OH;
- halogen;
- N(R₃)₂;

Application No.: 10/027,218

Case No.: 54913US111

-CO-N(R₃)₂;
-CO-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-(substituted aryl);
-heteroaryl;
-(substituted heteroaryl);
-heterocyclyl;
-(substituted heterocyclyl);
-CO-aryl; and
-CO-heteroaryl;

each R₃ is independently selected from the group consisting of hydrogen; C₁₋₁₀ alkyl-heteroaryl; C₁₋₁₀ alkyl-(substituted heteroaryl); C₁₋₁₀ alkyl-aryl; C₁₋₁₀ alkyl-(substituted aryl) and C₁₋₁₀ alkyl;

n is 0 to 4;

and each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof.

10. (original) A compound of claim 9 wherein n is 0.

11. (original) A compound of claim 9 wherein R₂ is selected from the group consisting of hydrogen, C₁₋₄ alkyl, and C₁₋₄ alkyl-O-C₁₋₄ alkyl.

12. (original) A compound of claim 9 wherein R₃ is hydrogen.

13. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:

(2*S*,3*S*)-*N*-(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl)-1-methyl-5-oxo-2-pyridin-3-ylpyrrolidine-3-carboxamide;

Application No.: 10/027,218

Case No.: 54913US111

N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-[(4-*tert*-butylphenyl)sulfonyl]-*L*-prolinamide;
N-[8-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)octyl]benzamide;
N-{8-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]octyl}benzamide;
N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]benzamide;
N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]-2,2-dimethylpropyl}benzamide;
N-[8-(4-amino-1*H*-imidazo[4,5-*c*]quinolin-1-yl)octyl]benzamide;
N-{3-[4-amino-2-(3-phenoxypropyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-4-bromobenzamide;
N-{3-[4-amino-2-(3-phenoxypropyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}benzamide;
N-{3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}benzamide; and
N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}benzamide; or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

14. (original) A compound selected from the group consisting of:

N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}isoquinoline-3-carboxamide;
N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}quinoline-3-carboxamide;
N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}quinoxaline-2-carboxamide;
N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]isoquinoline-3-carboxamide;
N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}isoquinoline-3-carboxamide;
N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclopentanecarboxamide;
N-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclohexanecarboxamide;
N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-2-methylpropanamide;

Application No.: 10/027,218

Case N .: 54913US111

N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]butanamide;
N-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclopentanecarboxamide;
N-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-2-methylpropanamide;
N-[4-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]butanamide;
N-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]cyclohexanecarboxamide;
N-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]cyclohexanecarboxamide;
N-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]cyclopentanecarboxamide;
N-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-methylpropanamide;
N-[3-(4-amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]butanamide; and
N-{2-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]-1,1-dimethylethyl}-2-ethoxyacetamide;
or a pharmaceutically acceptable salt thereof.

15. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 5 in combination with a pharmaceutically acceptable carrier.

16. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9 in combination with a pharmaceutically acceptable carrier.

17 (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14 in combination with a pharmaceutically acceptable carrier.

18. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 1 to the animal, wherein the cytokine is interferon- α or tumor necrosis factor- α .

19. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 4 to the animal, wherein the cytokine is interferon- α or tumor necrosis factor- α .

Application N .: 10/027,218

Case No.: 54913US111

20. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 13 to the animal, wherein the cytokine is interferon- α or tumor necrosis factor- α .

21. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 15 to the animal, wherein the cytokine is interferon- α or tumor necrosis factor- α .

22. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 16 to the animal, wherein the cytokine is interferon- α or tumor necrosis factor- α .

23. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a composition of claim 17 to the animal, wherein the cytokine is interferon- α or tumor necrosis factor- α .